Vitamin D Receptor as a Drug Discovery Target

Title: Vitamin D Receptor as a Drug Discovery Target

Volume: 3 Issue: 3

Author(s): Karen V. Pinette, Ying K. Yee, Bernard Y. Amegadzie and Sunil Nagpal

Affiliation:

Keywords: 25-dihydroxyvitamin, immunomodulatory, VDR ligands, osteoporosis, hydroxyvitamin

Abstract: 1α, 25-dihydroxyvitamin D3 [1,25 (OH)2D3], the active metabolite of vitamin D3, is known for the maintenance of normal skeleton architecture and mineral homeostasis. Apart form these traditional calcemic actions, 1,25 (OH)2D3 and its synthetic analogs are increasingly recognized for their potent anti-proliferative, prodifferentiative and immunomodulatory activities. The calcemic and non-calcemic actions of 1,25 (OH)2D3 and its synthetic analogs are mediated through vitamin D receptor (VDR), which belongs to the superfamily of steroid / thyroid hormone nuclear receptors. Physiological and pharmacological actions of 1,25 (OH)2D3 in various systems, along with the detection of VDR in target cells, have indicated potential applications of VDR ligands in inflammation, dermatological indications, osteoporosis, cancers and autoimmune diseases. VDR ligands have shown therapeutic potential in limited clinical trials as well as in animal models of these diseases. As a result, a VDR ligand, calcipotriol is in clinic for psoriasis and another, OCT, [2-oxa-1,25 (OH)2D3] is being developed as a topical agent for the same indication. Further, 1α,-hydroxyvitamin D3 (alphacalcidol), a prodrug of 1,25 (OH)2D3 is in clinic and a synthetic VDR ligand, ED-71, is under consideration for approval in Japan for the treatment of osteoporosis. Interestingly, VDR ligands have shown not only preventive but also potent therapeutic anabolic activities in animal models of osteoporosis. However, the wide spread use of VDR ligands in above-mentioned indications is hampered by their major side effect, namely hypercalcemia. In view of this associated toxicity, synthetic VDR ligands with reduced calcemic potential have been synthesized with the ultimate aim of improving their therapeutic efficacy. This review presents recent advances in VDR biology, novel VDR ligands and therapeutic applications of VDR ligands.

Cite this article as:

Pinette V. Karen, Yee K. Ying, Amegadzie Y. Bernard and Nagpal Sunil, Vitamin D Receptor as a Drug Discovery Target, Mini-Reviews in Medicinal Chemistry 2003; 3 (3) . https://dx.doi.org/10.2174/1389557033488204